Spark Therapeutics (ONCE) Given a $71.00 Price Target at Sanford C. Bernstein
Sanford C. Bernstein set a $71.00 price objective on Spark Therapeutics (NASDAQ:ONCE) in a report published on Wednesday. The brokerage currently has a buy rating on the biotechnology company’s stock.
Several other equities research analysts also recently commented on ONCE. Evercore ISI started coverage on shares of Spark Therapeutics in a research note on Wednesday, August 16th. They issued an in-line rating and a $83.00 target price for the company. Cantor Fitzgerald reaffirmed a buy rating on shares of Spark Therapeutics in a research note on Friday, August 25th. BidaskClub raised shares of Spark Therapeutics from a hold rating to a buy rating in a research note on Saturday, August 26th. Barclays started coverage on shares of Spark Therapeutics in a research note on Wednesday, September 6th. They issued an overweight rating and a $104.00 target price for the company. Finally, Royal Bank of Canada started coverage on shares of Spark Therapeutics in a research note on Thursday, September 14th. They issued an outperform rating and a $100.00 target price for the company. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and fifteen have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $76.19.
Shares of Spark Therapeutics (NASDAQ:ONCE) traded up $1.15 during trading hours on Wednesday, reaching $45.91. 1,895,700 shares of the company’s stock traded hands, compared to its average volume of 481,123. Spark Therapeutics has a 1 year low of $41.06 and a 1 year high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. During the same period in the previous year, the company posted ($1.07) EPS. The firm’s revenue for the quarter was up 45.8% on a year-over-year basis. equities research analysts forecast that Spark Therapeutics will post -7.6 EPS for the current fiscal year.
In other news, insider Daniel Faga sold 1,500 shares of the stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total transaction of $127,500.00. Following the completion of the sale, the insider now owns 1,500 shares of the company’s stock, valued at $127,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Barge Joseph La sold 5,500 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $71.44, for a total transaction of $392,920.00. Following the sale, the insider now directly owns 8,146 shares of the company’s stock, valued at approximately $581,950.24. The disclosure for this sale can be found here. Insiders have sold 1,068,809 shares of company stock valued at $89,809,385 in the last three months. 7.30% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Belpointe Asset Management LLC acquired a new position in Spark Therapeutics during the third quarter worth $403,000. Neuberger Berman Group LLC acquired a new position in Spark Therapeutics during the third quarter worth $672,000. Cubist Systematic Strategies LLC boosted its holdings in Spark Therapeutics by 257.7% during the third quarter. Cubist Systematic Strategies LLC now owns 8,588 shares of the biotechnology company’s stock worth $766,000 after purchasing an additional 6,187 shares during the last quarter. Perceptive Advisors LLC acquired a new position in Spark Therapeutics during the third quarter worth $16,049,000. Finally, Orbimed Advisors LLC acquired a new position in Spark Therapeutics during the third quarter worth $38,340,000. Institutional investors and hedge funds own 94.94% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Spark Therapeutics (ONCE) Given a $71.00 Price Target at Sanford C. Bernstein” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/12/14/spark-therapeutics-once-given-a-71-00-price-target-at-sanford-c-bernstein.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.